Abstract:
An apparatus, program product and method support the dynamic modification of cluster communication parameters such as a fragmentation size parameter through controllably deferring the processing of a requested fragmentation size change in a source node until after receipt an acknowledgment message for at least one unacknowledged message sent by the source node to a plurality of target nodes. By controllably deferring such processing until it is confirmed that any such previously-unacknowledged messages sent by a source node have been received by any target nodes, synchronization between the source node and the target nodes may be obtained, and a fragmentation size change may occur in a coordinated fashion such that future messages from the source node to the target node will be processed by both the source and the target nodes using the modified fragmentation size parameter.
Abstract:
Compositions and methods of treatment of interferon-responsive disorders are provided wherein the methods, for example, comprise orally administering a composition which comprises a therapeutically effective amount of at least one alkylated imino sugar having an alkylated side chain, and a pharmaceutically acceptable carrier.
Abstract:
Methods and compositions for modulating an immune response in a mammal infected with a bacterium, a virus, or a parasite are provided. The methods and compositions are useful in mammals experiencing an acute infection and in mammals experiencing a chronic infection. The methods and compositions may be used in conjunction with a known treatment for infection of a mammal by an infectious agent. Methods and compositions for transmucosal delivery of a molecule comprising an epitope located in close proximity to the immune response are provided.
Abstract:
Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immunostimulating agents.
Abstract:
A method and system for communication in a system area network (SAN) data processing system are described. The SAN includes a plurality of interconnected nodes that each have at least one port for communication. To avoid communication-induced errors that may arise, for example, if multiple nodes share the same node ID, the port of a node in the SAN is marked as “fenced” to prevent transmission of packets of a first traffic type while permitting transmission of packets of a second traffic type. The marking of the port may be recorded, for example, in a configuration register of the port. While the port is fenced, only packets of other than the first traffic type are routed via the port. In one preferred embodiment, the second traffic type represents SAN configuration traffic, and the first traffic type represents non-configuration traffic. In this preferred embodiment, the marking of the port may be removed following communication of configuration traffic utilized to negotiate unique node ID throughout the SAN.
Abstract:
Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immuno-stimulating agents.
Abstract:
Elevated levels of GP73 in the sera is diagnostic for hepatocellular carcinoma. An increase in serum GP73 levels over time can also indicate the onset of hepatocellular carcinoma in subjects at risk for the disease.
Abstract:
An apparatus, program product and method utilize cluster data port services within a cluster infrastructure to provide reliable and efficient communications between nodes in a clustered computer system. The cluster data port services present an abstracted transport service that encapsulates and manages the establishment of multiple connection paths between a source node, a target node and one or more backup nodes in such a manner that a cluster data port is effectively utilized as single data port from the perspective of a user program.
Abstract:
This disclosure describes a relevant etiology of cancer and a novel anti-cancer therapeutic strategy, based on the discovery that a protein named serine protease inhibitor (SPIK/SPINK/PSTI) was up-regulated by hepatitis B and C virus infections consequently suppressing the cell apoptosis. Accordingly, the present disclosure provides, inter alia, an inhibitor of SPIK and/or a technology of suppression of over-expression of SPIK in cells. The inhibitors include: 1) chemical compounds, which can inhibit SPIK transcripts, protein activity, and gene expression, 2) SPIK siRNA (RNAi gene silence or dsRNA of SPIK, 3) DNA anti-sense and anti-SPIK antibody. Further, this disclosure provides methods of using the inhibitor as an anti-cancer agent to re-instate cancer cell apoptosis (e.g., serine protease dependent cell apoptosis).
Abstract:
This invention describes a relevant etiology of cancer and a novel anti-cancer therapeutic strategy, based on the discovery that a protein named serine protease inhibitor (SPIK/SPINK/PSTI) was up-regulated by hepatitis B and C virus infections consequently suppressing the cell apoptosis. Accordingly, this invention provides an inhibitor of SPIK and/or a technology of suppression of over-expression of SPIK in cells. The inhibitors include: 1) chemical compounds, which can inhibit SPIK transcripts, protein activity, and gene expression, 2) SPIK siRNA (RNAi gene silence or dsRNA of SPIK, 3) DNA anti-sense and anti-SPIK antibody. Further, this invention provides a method of using the inhibitor as an anti-cancer agent to re-instate cancer cell apoptosis (e.g., serine protease dependent cell apoptosis).